首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Anidulafungin in Treatment of Experimental Invasive Infection by Candida parapsilosis: In Vitro Activity (1→3)-β-d-Glucan and Mannan Serum Levels Histopathological Findings and In Vivo Efficacy
【2h】

Anidulafungin in Treatment of Experimental Invasive Infection by Candida parapsilosis: In Vitro Activity (1→3)-β-d-Glucan and Mannan Serum Levels Histopathological Findings and In Vivo Efficacy

机译:Anidulafungin在治疗副翼念珠菌的实验性侵染中的作用:体外活性(1→3)-β-d-葡聚糖和甘露聚糖血清水平组织病理学发现和体内功效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We have evaluated the in vitro activity of anidulafungin (AFG) against 31 strains of Candida parapsilosis sensu stricto by using broth microdilution, disk diffusion, and minimal fungicidal concentration (MFC) determination procedures. The two first methods showed a high level of activity of the drug, while MFCs were 1 to 5 dilutions higher than their corresponding MICs. To assess if MICs were predictive of in vivo outcomes, six strains representing different AFG MICs (0.12 to 2 μg/ml) were tested in a murine model of disseminated infection treated with different doses of the drug (1, 5, or 10 mg/kg of body weight). AFG was able to prolong the survival of mice infected with all the strains tested but was able to reduce the tissue burden of those mice infected only with the strains that showed the lowest MIC (0.12 μg/ml).
机译:我们已经通过肉汤微稀释,圆盘扩散和最小杀真菌浓度(MFC)测定程序评估了阿尼芬净(AFG)对31株严格意义上的副念珠菌菌株的体外活性。前两种方法显示出高水平的药物活性,而MFC比其相应的MIC高1-5倍。为了评估MIC是否可预测体内结果,在用不同剂量药物(1、5或10 mg / ml)治疗的弥散性感染的鼠模型中测试了代表不同AFG MIC(0.12至2μg/ ml)的六株菌株公斤体重)。 AFG能够延长感染了所有测试菌株的小鼠的存活期,但能够减轻仅感染那些具有最低MIC(0.12μg/ ml)菌株的小鼠的组织负担。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号